BANK VONTOBEL/PUT/ROCHE GS/240/0.1/20.06.25 Share Price

Warrant

DE000VM7ZXL9

Delayed Deutsche Boerse AG 18:55:07 28/06/2024 BST
1.62 EUR +1.89% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/240/0.1/20.06.25
Current month-37.93%
1 month-40.66%
Date Price Change
28/06/24 1.62 +1.89%
27/06/24 1.59 -3.64%
26/06/24 1.65 +12.24%
25/06/24 1.47 +2.08%
24/06/24 1.44 -5.26%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 06:55 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM7ZXL
ISINDE000VM7ZXL9
Date issued 04/01/2024
Strike 240 CHF
Maturity 20/06/2025 (355 Days)
Parity 10 : 1
Emission price 2.07
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.84
Lowest since issue 1.43
Delta-0.41x
Omega 6.639
Premium10.11x
Gearing16.06x
Moneyness 0.9612
Difference Strike -10.05 CHF
Difference Strike %-4.19%
Spread 0.01
Spread %0.62%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus